Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials.

Benjamin L GreenAlisa N BlumenthalerLauren A GambleJames D McDonaldKristen RobinsonMaureen ConnollyMonica EpsteinJonathan M HernandezAndrew M BlakelyBrian D BadgwellJeremy Lee Davis

Published in: Annals of surgical oncology (2022)

In patients with gastric adenocarcinoma and isolated peritoneal metastasis treated with CRS-HIPEC, 3-year OS was 22% from CRS-HIPEC, and complications were common. The number of pathologic lymph node metastases was inversely correlated with overall survival. Further investigation of CRS-HIPEC for GA should include patient selection based on response to systemic chemotherapy or incorporate novel intraperitoneal treatment strategies.

Keyphrases

phase ii
clinical trial
lymph node
locally advanced
neoadjuvant chemotherapy
open label
pet ct
squamous cell carcinoma
phase iii
double blind
radiation therapy
risk factors
randomized controlled trial
placebo controlled
sentinel lymph node